2,222 Shares in Jazz Pharmaceuticals PLC $JAZZ Bought by Provenance Wealth Advisors LLC

Provenance Wealth Advisors LLC bought a new stake in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 2,222 shares of the specialty pharmaceutical company’s stock, valued at approximately $514,000.

Several other institutional investors have also recently made changes to their positions in JAZZ. Castleark Management LLC bought a new position in shares of Jazz Pharmaceuticals in the first quarter worth $9,214,000. SEB Asset Management AB bought a new stake in shares of Jazz Pharmaceuticals during the 1st quarter valued at $8,765,000. Bank of America Corp DE raised its stake in shares of Jazz Pharmaceuticals by 10.9% during the 1st quarter. Bank of America Corp DE now owns 1,014,800 shares of the specialty pharmaceutical company’s stock valued at $191,848,000 after purchasing an additional 99,656 shares during the period. California Public Employees Retirement System raised its stake in shares of Jazz Pharmaceuticals by 10.6% during the 1st quarter. California Public Employees Retirement System now owns 124,583 shares of the specialty pharmaceutical company’s stock valued at $23,552,000 after purchasing an additional 11,915 shares during the period. Finally, Angeles Wealth Management LLC purchased a new stake in Jazz Pharmaceuticals during the 2nd quarter worth about $1,221,000. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals News Summary

Here are the key news stories impacting Jazz Pharmaceuticals this week:

• Positive Sentiment: Jazz beat Q3 2026 estimates, reporting revenue of $1.24 billion versus expectations of $1.21 billion, with revenue up 10.4% year over year. The company also raised its 2026 revenue outlook to approximately $4.78 billion–$4.85 billion, according to the earnings coverage. Q3 earnings call summary
• Positive Sentiment: Several firms, including RBC, Barclays, Morgan Stanley and JPMorgan, issued bullish commentary or raised price targets after the results, signaling continued analyst confidence. Barclays price target coverage
• Neutral Sentiment: CEO Renée Galá sold 1,000 shares and director Bruce Cozadd sold 6,000 shares. Both transactions were made under pre-arranged Rule 10b5-1 plans; Galá retained 140,394 shares and Cozadd retained 339,875. Planned sales are less informative about executives’ current views than discretionary transactions. CEO sale filing

Wall Street Analysts Forecast Growth

JAZZ has been the subject of several analyst reports. Royal Bank Of Canada raised their target price on Jazz Pharmaceuticals from $296.00 to $305.00 and gave the stock an “outperform” rating in a research note on Tuesday. Piper Sandler upped their price target on Jazz Pharmaceuticals from $301.00 to $310.00 and gave the company an “overweight” rating in a research report on Tuesday, August 4th. TD Cowen upped their price target on Jazz Pharmaceuticals from $275.00 to $300.00 and gave the company a “buy” rating in a research report on Tuesday, August 4th. Needham & Company LLC increased their price target on shares of Jazz Pharmaceuticals from $292.00 to $310.00 and gave the stock a “buy” rating in a report on Wednesday, August 26th. Finally, Deutsche Bank Aktiengesellschaft raised their price objective on shares of Jazz Pharmaceuticals from $287.00 to $300.00 and gave the company a “buy” rating in a research report on Wednesday, August 26th. One research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $293.45.

Jazz Pharmaceuticals Stock Down 3.1%

JAZZ opened at $227.32 on Friday. The company has a fifty day moving average price of $229.71 and a 200-day moving average price of $217.40. The firm has a market capitalization of $14.59 billion, a P/E ratio of 77.32, a price-to-earnings-growth ratio of 0.47 and a beta of 0.38. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.82 and a quick ratio of 1.58. Jazz Pharmaceuticals PLC has a one year low of $128.80 and a one year high of $266.38.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its quarterly earnings results on Monday, November 2nd. The specialty pharmaceutical company reported ($3.88) earnings per share for the quarter, topping the consensus estimate of ($4.03) by $0.15. Jazz Pharmaceuticals had a net margin of 4.37% and a return on equity of 16.88%. The firm had revenue of $1.24 billion for the quarter, compared to analysts’ expectations of $1.21 billion. During the same quarter in the prior year, the firm posted $8.13 earnings per share. The business’s quarterly revenue was up 10.4% on a year-over-year basis. Equities research analysts expect that Jazz Pharmaceuticals PLC will post 10.84 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Jazz Pharmaceuticals news, EVP Robert Iannone sold 76,921 shares of the company’s stock in a transaction dated Thursday, August 27th. The stock was sold at an average price of $249.70, for a total value of $19,207,173.70. Following the transaction, the executive vice president directly owned 65,686 shares in the company, valued at $16,401,794.20. This represents a 53.94% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Renée Galá sold 2,000 shares of the company’s stock in a transaction dated Tuesday, October 6th. The stock was sold at an average price of $236.40, for a total value of $472,800.00. Following the completion of the transaction, the chief executive officer owned 141,394 shares in the company, valued at $33,425,541.60. This represents a 1.39% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 101,121 shares of company stock valued at $24,858,332 in the last ninety days. Corporate insiders own 4.10% of the company’s stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing medicines for neurological, sleep-related and oncology disorders. The company serves patients and healthcare providers in the United States and international markets, with products marketed through its commercial operations and partnerships.

Jazz’s sleep portfolio includes Xyrem and Xywav, which are used to treat certain symptoms associated with narcolepsy. Following its acquisition of GW Pharmaceuticals, the company also added Epidiolex, a cannabidiol-based treatment for specific forms of treatment-resistant epilepsy.